Management Team

Pascal Touchon President and Chief Executive Officer

With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Pascal has committed his career to transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence.

Previously Global Head, Cell & Gene and member of the Oncology Executive Committee at Novartis Oncology, he oversaw the Oncology Cell & Gene unit and had responsibility for the unit’s financial performance and its activities, including the global launch of KYMRIAH® (tisagenlecleucel), securing regulatory approval and reimbursement in major markets, expanding global CAR T manufacturing and technical operations, overseeing multiple new clinical studies, and building a strong leadership team.

Prior to that, he served as Global Head, Strategy, Business Development, Oncology at Novartis, where he was responsible for early commercial strategy, portfolio management, therapeutic integrity and established medicines, disruptive technologies, diagnostics, business development and external collaborations, and served as a member of the Oncology Executive Committee. Pascal has also held key leadership roles in research, marketing, general management, and business development at companies including Servier, Glaxo-Wellcome and Glaxo, Sanofi. He has also been a board member of Genoptix and Navigate Biopharma Services (Novartis companies) and Cogen Therapeutics (a Flagship Pioneering company).

Pascal holds a doctorate in veterinary medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Superieures Specialisees (DESS) in management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Beyond his passion for science and business, Pascal enjoys traveling with his family around the world, wine tasting with friends, watching rugby, and reading.

Jakob Dupont, M.D. Head of Global Research & Development

Dr. Dupont is a renowned expert in the fields of cell therapy and oncology, with long-standing and deep experience in developing therapies and programs dedicated to addressing high unmet medical needs. Dr. Dupont serves as Global Head of Research & Development (R&D) including Medical and Regulatory Affairs. Prior to joining Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Dr. Dupont is committed to bringing transformative therapies to patients.

Prior to his role at Gossamer Bio, he served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin® (trastuzumab), Perjeta® (pertuzumab), Kadcyla® (ado-trastuzumab emtansine), and Tecentriq® (atezolizumab), among others. Prior to that, Dr. Dupont was Chief Medical Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc., where he oversaw the successful submissions of eight investigational new drug applications (INDs) and 26 clinical trial initiations.

Dr. Dupont has been involved in tumor immunology research and clinical investigations for more than 25 years, ranging from cellular therapy to tumor vaccine therapy and immune checkpoints. Dr. Dupont has received numerous grants and awards, and has co-authored 47 peer-reviewed publications, has 30 patents, and has also served as a faculty member and laboratory researcher at Memorial Sloan Kettering Cancer Center (MSK) and adjunct clinical faculty in medical oncology at Stanford University.

Dr. Dupont received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University, his M.A. in philosophy from New York University, and his undergraduate degree in philosophy from Vassar College. He also served as Assistant Chief Resident and completed his Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSK), his Internal Medicine Residency at the New-York Presbyterian Hospital — Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center.

Jakob and his family live in the Bay Area and enjoy outdoor activities including skiing, tennis, and canoe camping. Jakob is also an avid cook, gardener, and soccer fan.

Joe Newell Chief Operations Officer

Joe Newell is the Chief Operations Officer for Atara, overseeing Process Sciences, Manufacturing, Quality, Program Management, Alliance Management, and Enterprise Services.  He has extensive experience in product development, operational and quality management, and continuous improvement. Joe is a values-based leader passionate about cross-functional teamwork that results in delivering transformative medicines for patients through his role at Atara.

Prior to joining Atara in 2017 to lead Technical Operations, he served as Vice President, Manufacturing at Alexion Pharmaceuticals, where he was responsible for leading bulk drug substance manufacturing operations across seven facilities in the United States and supporting global expansion efforts in Ireland.

Previously, Joe spent several years at Amgen, where he served in multiple global leadership roles across Manufacturing and Supply Chain.  Earlier in his career, he held operational and entrepreneurial leadership roles with Catalent, Cardinal Health, Matrix Pharmaceutical, and Stanford Research Institute (SRI International).

Joe holds a B.S. in biology from California Polytechnic University, Pomona.

Away from work, he is dedicated to his wife and three children and enjoys the outdoors, sports, and a variety of restoration projects.

Utpal Koppikar Chief Financial Officer

Utpal Koppikar is the Chief Financial Officer of Atara Biotherapeutics, a position he has held since joining the company in June 2018. In this role, Utpal oversees Finance, Information Technology, and Investor Relations. Through a commitment to Atara’s mission of transforming the lives of patients with serious medical conditions, Utpal’s organization helps enable the advancement of our investigational medicines to commercialization.

Prior to his tenure with Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance, in which he was responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma, upon that company’s acquisition by Gilead in October 2017.  Before that, Utpal played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia, in partnering with the commercial division for multiple product launches in the HIV and HCV franchises.

Prior to Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. He began his career at Honeywell Aerospace (formerly AlliedSignal).

Utpal earned his B.S. in aerospace engineering at the University of Maryland and received a M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an MBA in finance and marketing from The Anderson School at UCLA.

Away from work, Utpal enjoys spending time with his wife and two teenagers, traveling, and mentoring aspiring young aviators.

Kristin Yarema, Ph.D. Chief Commercial Officer

With more than 20 years of biopharmaceutical experience ranging from research to bringing products to market, Dr. Kristin Yarema was named Atara’s Chief Commercial Officer in February of 2020.

Kristin came to Atara after serving as Amgen’s Vice President & Therapeutic Area Head, Global Product Strategy & Commercial Innovation, Hematology and Oncology. In her seven years at Amgen, Dr. Yarema strategically managed the company’s pipeline in small molecule and immuno-oncology for hematological malignancies, such as multiple myeloma, leukemias, and lymphomas, and was recognized as having the top therapeutic area in 2018 while leading the Cardiovascular, Metabolism and Neuroscience business unit.

Prior to joining Amgen, Dr. Yarema held global roles for Novartis and McKinsey & Company, where she led project teams for companies across the U.S., Europe, and Asia.

Dr. Yarema graduated from University of California, Berkeley with a Ph.D. in Biochemical/Biomedical Engineering and Stanford University with a B.S. in Chemical Engineering with Distinction and B.A. in English with Distinction.  In addition, she has served on the Board of Directors for the Celiac Disease Foundation, the U.S.-based patient-advocacy group.

Dr. Yarema is proficient in Advanced German and basic French and in her free time, enjoys cycling, music, food, wine, yoga and travel.

Amie Krause Chief People Officer

Amie Krause is the Senior Vice President and Chief People Officer at Atara Biotherapeutics. In her role, Amie strives to foster an environment where all Atarians feel motivated to work together to realize the organization’s overall mission and build a company culture that rewards our values through actions and results. Since joining Atara, Amie has overseen nearly every function within the human people department.

Amie is a strategic and agile HR executive with 25 years of experience bringing expertise in talent acquisition, employee relations, compensation, benefits, leadership development, coaching and operations. Prior to her tenure with Atara, Amie held several HR leadership positions at Amgen, including her role as Global HR Lead, Organizational Effectiveness during which she served as the human resources lead for Amgen’s global commercial operations covering the Americas, Europe, Asia, and the Middle East. Additionally, she served the Commercial HR lead standing up Amgen’s cardiovascular franchise launching two products.

Amie is passionate about diversity, equity and inclusion and was a founding leader of the Atara Women’s Alliance (AWA). She has been a strong advocate for the LGBTQ community at Atara and is an active member of the Healthcare Businesswomen’s Association (HBA).

Amie holds both a B.S. in business management and an MBA from California Lutheran University. She has also completed the UC Berkeley Extension program for Human Resources Officers.

Away from the office, Amie doubles as a professor at the California Lutheran University School of Management and guest lecturer at the USC School of Healthcare Decision Analysis. Outside of work, Amie enjoys movies, reading, Dodgers baseball, weight lifting, and spending time with her husband, Mike and two kids, Natalie and Nick.

AJ Joshi, M.D. Chief Medical Officer

Manher (AJ) Joshi was appointed to the role of Atara Biotherapeutics’ Chief Medical Officer in September 2018. He joined Atara in August 2016, initially serving as Senior Vice President, Global Medical Affairs. He brings more than 15 years of clinical, drug development, and commercialization experience in orphan and large markets to his role at Atara.

AJ has built and led medical organizations through several launches across a broad range of therapeutics areas, including neuromuscular disease, neurosciences, genetics, metabolic diseases, urology, and dermatology. His previous organizational leadership roles include U.S. Medical Affairs Therapeutic Area Head at Allergan, SVP Strategic Development and Medical Operations at Synageva, and Vice President Medical Affairs and Operations at Genzyme.

AJ received his M.D. from the Boston University School of Medicine, his B.A. from Boston University, and completed his internship and residency in medicine at Yale.

In his free time, AJ enjoys photography, traveling, and playing the guitar.

Cokey Nguyen, Ph.D. Chief Scientific Officer

Dr. Cokey Nguyen is a leader in the fields of cell therapy and oncology with significant experience in research and development of cell therapies as well as oncology drug discovery and development in biotech. Dr. Nguyen serves as Chief Scientific Officer at Atara, where he is focused on leading the development of next-generation allogeneic cell therapies for cancer and autoimmune diseases. With his passion for delivering transformative therapies to patients, Dr. Nguyen is eager to both advance Atara’s existing programs and further expand the pipeline through pioneering science, teamwork, and a commitment to excellence.

Prior to joining Atara, Dr. Nguyen was at Fate Therapeutics, where, as Vice President, Innovation, Research and Development, he directed strategy for discovery and innovation efforts, and spearheaded the corporate collaboration program with ONO Pharma. Prior to that, he was leader of the targeted immunotherapy group on the Oncology R&D team at Pfizer, producing bispecific antibodies for solid tumors and hematological malignancies and bringing them into the clinic.

Dr. Nguyen’s bench science experience includes work in tumor metabolism, gene expression and molecular biology. He holds numerous patents for iPSC and immune effector cells and has been published in various peer-reviewed journals. Dr. Nguyen has also been active in successful business development activities, including, while at Janssen, evaluating Legend’s BCMA-directed CAR T program and supporting the Janssen/Legend partnership.

Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology (MIT), where he focused on the identification and characterization of BRCT domains as novel phospho-binding domains in DNA damage pathways.

In his free time, Cokey is an avid reader, is a fan of motorsports and enjoys cycling.

Dan Maziasz Head of Corporate Strategy and Business Development

Dan Maziasz is the Senior Vice President and Head of Corporate Strategy & Business Development at Atara Biotherapeutics. In his role, Dan is responsible for leading Atara’s corporate strategy, business development and alliance management activities including strategic partnerships, licensing transactions, research collaborations and academic partnerships.

Prior to joining Atara in 2018, Dan served as Vice President, Corporate Strategy and Business Development at Gilead Sciences following its acquisition of Kite Pharma. In his role at Kite/Gilead, Dan led various strategy and business development initiatives focused on new product opportunities, enabling technologies, and was responsible for Kite’s Joint Venture in China and strategic partnership in Japan. Prior to joining Kite, he held roles of increasing responsibility at Amgen in the U.S., Europe, Asia and emerging market regions across Business Development, Corporate Strategy, Finance and Commercial. Dan began his career as a management consultant by advising large and small companies across healthcare, financial services and other industries.

Dan received a B.S. in Business Administration and Economics from Saint Mary’s College of California and a M.B.A. degree from Loyola Marymount University.

In his personal time, Dan enjoys international travel, music, basketball, skiing and spending time with his wife and three children.

Jill Henrich Head of Global Regulatory Affairs

Jill Henrich is the Senior Vice President, Global Regulatory Affairs at Atara Biotherapeutics. She is excited to utilize her more than 20 years of experience in regulatory affairs, as well as her background in research to deliver transformative medicines to patients through her role at Atara.

Jill came to Atara from OncoMed Pharmaceuticals, a wholly owned subsidiary of Mereo BioPharma where she served as U.S. Site Head and Senior Vice President of Regulatory Affairs. Before the merger in 2019, she was Senior Vice President, Regulatory Affairs and Quality, providing oversight on all aspects of global Regulatory Affairs and Quality Assurance strategy, implementation and execution. In her most recent time at OncoMed, Jill successfully negotiated an accelerated approval pathway for a DLL4/VegF bispecific antibody for the treatment of ovarian cancer at an FDA EOP1 meeting and gained agreement from FDA at an EOP2 meeting on the design of a single pivotal pediatric Phase 3 study for patients with osteogenesis imperfecta, a rare disease affecting children. She has led numerous meetings with the EMA and other European regulatory bodies for the setrusumab program through PRIME Designation and Adaptive Pathways. In addition, she was responsible for successfully filing and executing 14 Investigational New Drug (IND) applications for 9 novel programs in oncology.

Prior to joining OncoMed, she served as Executive Director, Regulatory Affairs and Quality Assurance at PDL BioPharma, Inc. providing strategic management and oversight for all regulatory interactions, Regulatory Operations/Corporate Document Control, Medical Writing and QA/Compliance activities. Jill also held a similar role at Corixa Corporation (formerly Coulter Pharmaceutical, Inc.) where she was instrumental in the filing and approval of an iodine-131 radiolabeled anti-CD20 monoclonal antibody for the treatment of non-Hodgkin’s lymphoma. In addition, she has held various positions in Research (Cell Genetics/Molecular Biology) and Regulatory Affairs at Genentech, where she maintained global regulatory responsibility for two approved marketed products and multiple products in various phases of development.

Jill holds a B.S. in Biological Sciences/Microbiology from the University of Connecticut.

In her free time, Jill enjoys the outdoors and is an avid mountain and road biker and hiker. She has also recently taken up bread baking.

Tim Valko Head of Global Manufacturing and Supply Chain

An accomplished operations professional with more than 25 years of leadership in biopharmaceutical manufacturing, operations strategic planning, and clinical and commercial supply chain, Tim Valko serves as Senior Vice President, Global Manufacturing and Supply Chain. In his role, Tim brings a commitment to excellence and cross-functional teamwork with the aim to deliver Atara’s immunotherapies to patients.

Tim has been involved in the launch and commercial supply for more than 20 marketed biopharmaceutical products. Prior to joining Atara in 2017 as Vice President, Supply Chain, Tim held various leadership roles at Amgen, including leadership of Site Supply Chain, Bulk Manufacturing, Global Supply Chain, Operations Risk Management, and Strategic Planning across Amgen’s global manufacturing network. He brings additional experience from vaccine and biopharmaceutical production at Warner Lambert/Parke-Davis and Pfizer in Michigan, including leadership roles across Manufacturing, Inspection and Packaging for Sterile Drug Products, Clinical Supply Chain, and Global Pharmaceutical Sciences.

Tim is currently Board Chair, Rx-360 Supply Chain consortium, an industry-led nonprofit that addresses biopharmaceutical and device supply-chain security to public health concerns and patient safety.

Tim received his bachelor’s degree in biology at Adrian College, Adrian, Michigan.

Away from work, Tim enjoys time with his wife and two daughters, exploring the outdoors, as well as hiking, biking, paddling, and archery.

José Eduardo Vidal, Ph.D. Head of Quality Assurance and Process Sciences

José Eduardo Vidal serves as SVP, Quality Assurance and Process Sciences. He joined Atara Biotherapeutics in that role in August 2018. José is responsible for leading and advancing the Chemistry, Manufacturing and Control (CMC) components of our allogeneic T-cell therapy, including Quality and Quality Control Operations; functionality and compliance; scientific product, process, and analytical development; successful global regulatory approval; and preparation for commercial launch. He also manages the product and process development pipeline from preclinical stage through commercialization, as well as the industrialization of our cell therapy manufacturing process.

With more than 20 years of expertise in the development of biopharmaceuticals worldwide, José is dedicated to bringing our medicines to patients through pioneering science, teamwork, and a commitment to excellence.

Prior to Atara, José served as Vice President of Global Drug Product Process Development and Vice President of Drug Substance Operations at Amgen. At Amgen, he oversaw 1,200 employees and managed a $500 million budget across their global drug substance manufacturing network, as well as managed Amgen’s drug product process development of a multi-stage product pipeline.

José also held several senior roles at Wyeth and Pfizer, where he was responsible for leading Manufacturing Operations, Product and Process Development, and Quality Operations across multiple global and local sterile manufacturing operations. He has worked in numerous start-ups, including Biovail, as Head of Tech Transfer and Product Development.

José has been involved in the development of more than 100 products, as well as technology transfer, regulatory filing, and product launch in jurisdictions around the globe.

José received his bachelor’s degree in molecular biology, master’s degree in molecular endocrinology and biochemistry, and doctorate in cellular molecular biology, all from the University of Puerto Rico, Rio Piedras.

Away from work, José, an experienced and avid boater, enjoys sea boating adventures with his family.

K. Amar Murugan General Counsel

Amar Murugan joined Atara as Senior Vice President, General Counsel in April 2020. With more than 20 years of legal expertise, Amar is excited to employ his significant experience to deliver on Atara’s mission of transforming the lives of patients with serious medical conditions.

Prior to Atara, Amar served as Senior Vice President and General Counsel of Assertio Therapeutics, a commercial stage pharmaceutical company. During his time at Assertio, he managed all legal aspects of more than $1.5 billion of acquisitions and divestitures, nearly $1.0 billion of capital raising transactions and all SEC disclosure and governance matters.  Amar also managed a broad array of litigation, including patent, securities, and antitrust litigation; handled numerous government inquiries and investigations; and had oversight of the compliance function.  Amar has a track record of achieving outstanding legal outcomes, including the successful defense of a hostile takeover attempt, securing a multi-million-dollar settlement of an offensive patent litigation, and defeating a securities class action matter at the motion to dismiss stage.

Prior to Assertio, Amar was a partner in the global law firm of Baker Botts LLP, and prior to that, McDermott Will & Emery LLP, where he served as outside general counsel for public and private life science and technology companies and executed on numerous M&A transactions, venture capital financings, IPOs, public offerings, private placements, collaborations, and commercial arrangements. Amar began his legal career at Heller Ehrman LLP.

Amar holds a B.S. from Georgetown University and a J.D. from UCLA.  Away from work, Amar enjoys spending time with his wife and three children, traveling abroad, visiting his native Wisconsin, and exploring the great outdoors.